Articles On Monash IVF Group (ASX:MVF)
| Title | Source | Codes | Date |
|---|---|---|---|
|
5 ASX All Ords shares trading ex-dividend on Thursday
In the wake of ASX reporting season, weâve seen droves of companies in the S&P/ASX All Ordinaries Index (ASX: XAO) turn ex-dividend in recent weeks. When a companyâs shares turn ex-dividend, they no longer trade with the recent div... |
Motley Fool | MVF | 3 years ago |
|
ScoPo’s Powerplays: ASX health stocks finish reporting season in pretty strong shape
The ASX healthcare index has fallen this week as a strong reporting season comes to a close with outlook still positive for FY23 Clinuvel Pharmaceuticals (ASX:CUV) jumps up more than 14% this week on positive FY22 results including revenue... |
Stockhead | MVF | 3 years ago |
|
6 ASX shares Morgans would buy right now
We’re almost at the end of reporting season, so it’s time to think about which ASX shares might have the best prospects after the flurry of numbers. Morgans analyst Andrew Tang cast his eyes over the company results and has nominated six A... |
Motley Fool | MVF | 3 years ago |
|
Best calls to action – Monday, 29 August
Today, Monday the 29th of August, we are happy to buy Wesfarmers Limited (ASX:WES), Ramsay Health Care (ASX:RHC), Universal Store (ASX:UNI), Peter Warren (ASX:PWR), Jumbo Interactive (ASX:JIN) and Monash IVF Group (ASX:MVF). |
Morgans | MVF | 3 years ago |
|
ScoPo’s Powerplays: Reporting season positive as ASX health stocks head in right direction
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX Powerplays. ASX health sector modestly up... |
Stockhead | MVF | 3 years ago |
|
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | MVF | 3 years ago |
|
CRITERION: It’s a small cap smorgasboard with takeover targets on the table
The takeover action evident at the top end of town is trickling down to the small and mid cap sectors, as mainly foreign marauders avail of the undervalued morsels on offer. In theory, the end of cheap money should have crimped takeover act... |
Stockhead | MVF | 3 years ago |
|
ScoPo’s Powerplays: Much needed July rally for beaten-down ASX health stocks
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in ASX health stocks. ASX health stocks get much needed July rally aft... |
Stockhead | MVF | 3 years ago |
|
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | MVF | 3 years ago |
|
Evening Report: 1 July, 2022
ShareCafeEvening Report: 1 July, 2022 by Lauren Evans The Australian sharemarket faded into the close, weighed down by US equity futures in a risk-off afternoon. The greenback rose against the Australian dollar, which has fallen to its lo... |
ShareCafe | MVF | 3 years ago |
|
Monash IVF (ASX:MVF) to acquire ART Associates Queensland
01 Jul 2022 - Monash IVF (ASX:MVF) is set to acquire ART Associates Queensland in Brisbane for initial cash consideration of $3.9 million. |
FNN | MVF | 3 years ago |
|
Memphasys (ASX:MEM) enrols first patients into fertility study
Memphasys (MEM) has enrolled and treated the first couple under a clinical study trialling the safety and performance of its Felix device The study is being conducted with reproductive and fertility services company Monash IVF Group and w... |
themarketherald.com.au | MVF | 3 years ago |
|
Buy these good value ASX dividend shares: brokers
There are two main ways that the ASX share market can deliver returns for investors â capital growth and dividends. What if there are some ASX dividend shares that are expected to deliver dividends and potentially grow in value? Experts... |
Motley Fool | MVF | 3 years ago |
|
ScoPo’s Powerplays: Who stands out in the enterprise imaging sector?
ASX healthcare index finishes another week in the red Enterprise imaging stocks tipped to be a first recovery The goliath battle for fertility company Virtus comes to an end Healthcare and life sciences expert Scott Power – a senior analy... |
Stockhead | MVF | 3 years ago |
|
ScoPo’s Powerplays: Health stocks strap in for a ‘skittish’ ride
ASX Health stocks endure another topsy-turvy week ending in red Monash IVF makes two key purchases to expand its foothold in fertility sector Actinogen Medical to push ahead with trial into treatment of early Alzheimer’s disease. Healthca... |
Stockhead | MVF | 3 years ago |
|
Two ASX healthcare stocks AHX & RHC expand business with new acquisitions
Highlights Acquisitions have proven to be a great way for business expansion AHX has implemented binding agreements to acquire the assets of Victorian Equine Group and Romsey Veterinary Surgery Ramsay recently completed 100% acquisiti... |
Kalkine Media | MVF | 3 years ago |
|
Monash IVF Group (ASX:MVF) acquires PIVET Medical Centre for $9.4m
Monash IVF Group (MVF) acquires PIVET Medical Centre, marking its foray into the Western Australian IVF services market Monash IVF will pay an initial upfront cash consideration of $9.4 million, with the potential for additional earn out p... |
themarketherald.com.au | MVF | 3 years ago |
|
Monash IVF to enter WA market after agreeing initial $9.4m deal to acquire fertility provider PIVET
Reproductive care specialist Monash IVF Group (ASX: MVF) has entered into a binding sale agreement to acquire Perth-headquartered PIVET Medical Centre (PIVET) for an initial upfront cost of $9.4 million. Founded in 1981 by in vitro fertili... |
businessnewsaustralia.com | MVF | 3 years ago |
|
Why BlueScope, Firefinch, Monash IVF, and South32 shares are pushing higher
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.9% to 7,178.4 points. Four ASX shares that are rising more than most today are listed below.... |
Motley Fool | MVF | 3 years ago |
|
Monash IVF (ASX:MVF) widens clinical footprint, snaps up PIVET Medical Centre
Highlights Monash has inked a binding sale agreement to acquire PIVET Medical Centre, a fertility services provider based in Perth PIVET’s IVF Program resulted in Australia’s first IVF baby being born in 1982 An attractive growth oppo... |
Kalkine Media | MVF | 3 years ago |
|
Monash IVF Group enters WA market with acquisition of Pivet Medical Centre
Monash IVF Group has made its first foray into the WA market with the acquisition of respected fertility services provider Pivet Medical Centre. |
The West | MVF | 3 years ago |
|
Lunch Report: 18 May, 2022
ShareCafeLunch Report: 18 May, 2022 by Melissa Darmawan Materials lift ASX higher for 4th day Australian shares are on track to continue its winning streak for its fourth straight day after taking a strong lead from Wall St. The local ind... |
ShareCafe | MVF | 3 years ago |
|
ASX 200 opens 0.4% higher on positive global cues; BHP, FMG jump
Highlights: The benchmark ASX 200 index was up 0.44% at 7,143.80 points in the opening trades on Wednesday The Materials and Information Technology sectors led gains today Andrew Forrest is back at the helm of Fortescue Metals Group’s... |
Kalkine Media | MVF | 3 years ago |
|
Why Imugene, Integrated Research, Monash IVF, and Step One shares are sinking
The S&P/ASX 200 Index (ASX: XJO) is having a reasonably positive start to the week. In afternoon trade, the benchmark index is up 0.35% to 7,100 points. Four ASX shares that have failed to follow the market higher today are listed belo... |
Motley Fool | MVF | 3 years ago |
|
Why A2 Milk, Gold Road, GrainCorp, and Monash IVF shares are dropping
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up a sizeable 1.8% to 7,063.9 points. Four ASX shares that have failed to follow the m... |
Motley Fool | MVF | 3 years ago |
|
Why Block, IDP Education, Monash IVF, and Xero shares are dropping
The S&P/ASX 200 Index (ASX: XJO) is back heading south again on Thursday afternoon. At the time of writing, the benchmark index is down 1.5% to 6,961 points. Four ASX shares that are falling more than most are listed below. Here’s why... |
Motley Fool | MVF | 3 years ago |
|
From Tower to Turaco Gold: 10 ASX stocks with best past-year returns
Highlights The Australian share market opened in the green on Wednesday. Investors now have their eyes set on the US Federal Reserve’s potential rate hike decision. In such a scenario, investors are in search of stocks with... |
Kalkine Media | MVF | 3 years ago |
|
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | MVF | 3 years ago |
|
ScoPo’s Powerplays: ASX health stocks back in favour… or is it flavour?
The ASX healthcare sector rebounds on back of $20 billion Ramsay Healthcare takeover bid Volpara founder and CEO steps into new role as female CEO takes the reins Medlab Clinical shares soar after UK trade deal for probiotic for patients... |
Stockhead | MVF | 3 years ago |
|
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | MVF | 3 years ago |
|
ScoPo’s Powerplays: Green shoots appear among smaller ASX health stocks
S&P/ASX 200 healthcare index modestly up 0.16% for week Gut health company Microba falls on IPO Rhythm Biosciences bowel cancer blood screening test milestone Have a habit of forgetting where you put your keys or mobile phone? You ma... |
Stockhead | MVF | 3 years ago |
|
ScoPo’s Powerplays: Which ASX health stocks are winners from the Federal Budget?
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in ASX health stocks. Good news for coffee lovers, particularly those w... |
Stockhead | MVF | 3 years ago |
|
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | MVF | 3 years ago |
|
ScoPo’s Powerplays: These ASX health stocks are under the radar as market wallows
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Through the destruction of war... |
Stockhead | MVF | 3 years ago |
|
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal... |
Stockhead | MVF | 3 years ago |
|
ScoPo’s Powerplays: Who’s pulling for a health sector recovery?
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. First a note on things are are... |
Stockhead | MVF | 3 years ago |
|
ASX opens in green; IPH & CSL top gainers, Codan falls 6%
Highlights The ASX 200 surged 0.61% to 7,316.7 in the first 15 minutes of trade. Gold prices rose on Wednesday after NATO and the US stated that Russia was deploying more troops near Ukraine border. The IT space has tumbled 2.13% so f... |
Kalkine Media | MVF | 3 years ago |
|
ASX Health Stocks: Amplia Therapeutics gains momentum on pancreatic cancer drug
At the time of writing, the ASX 200 Health Index (XHJ) is up by another 3.3%, while the benchmark ASX 200 has risen by 0.5%. Cancer and fibrosis focused biotech Amplia Therapeutics (ASX:ATX) said its AMP945 drug improves effectiveness of cu... |
Stockhead | MVF | 3 years ago |
|
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby... |
Stockhead | MVF | 3 years ago |
|
2 ASX small-cap shares breaking multi-year highs today
It’s an exciting day for owners of these ASX small-cap shares – they’re hitting their highest share price in years. Shares in both Monash IVF Group Ltd (ASX: MVF) and Maggie Beer Holdings Ltd (ASX: MBH) are revelling in reporting season. T... |
Motley Fool | MVF | 3 years ago |
|
Healthcare Reporting Season Preview
We go over the key stocks we are looking out for in the Healthcare sector this February Reporting Season. Stocks include; ResMed Inc (ASX:RMD), Pro Medicus (ASX:PME), Healius (ASX:HLS), Virtus Health (ASX:VRT), Monash IVF (ASX:MVF), and CSL... |
Morgans | MVF | 3 years ago |
|
ScoPo’s Powerplays: Who’s staying afloat the inflation storm?
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Here’s something for anyone who... |
Stockhead | MVF | 3 years ago |
|
The Monash IVF (ASX:MVF) share price is gaining 6% today. Here’s why
Key points The Monash IVF share price has lifted nearly 6% today It comes after COVID-19 IVF restrictions were lifted in Victoria The company will resume IVF services next week The Monash IVF Group Ltd (ASX: MVF) share price is ri... |
Motley Fool | MVF | 3 years ago |
|
Monash IVF Group (ASX:MVF) suspends certain procedures in Victoria
Following new health orders in Victoria, Monash IVF Group (MVF) says non-urgent surgery protocols will disrupt some IVF procedures in Melbourne and other major centres The group says patients who plan to commence a stimulated cycle after J... |
themarketherald.com.au | MVF | 3 years ago |
|
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc
At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform... |
Stockhead | MVF | 3 years ago |
|
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %... |
Stockhead | MVF | 3 years ago |
|
MoneyTalks: Here’s why 2022 is going to be a stock picker’s market
MoneyTalks is Stockhead’s regular recap of the stocks, sectors and trends that ASX fund managers and analysts are looking at right now and into 2022. Today we hear from Julian Guido from Perennial Partners‘ Value Smaller Companies Trust whe... |
Stockhead | MVF | 3 years ago |
|
4 ASX shares tipped for buybacks in 2022: expert
An ASX company sometimes buys back its own shares, as a way to return capital to investors. Such actions are not necessarily received well, according to Allan Gray portfolio manager Dr Suhas Nayak. “Some argue that it shows a lack of growt... |
Motley Fool | MVF | 3 years ago |
|
Irongate Group announces acquisition of two properties and institutional placement; guidance upgraded
SYDNEY, Dec. 9, 2021 /PRNewswire/ — Irongate Group (ASX: IAP; JSE: IAP) has today announced the acquisition of an industrial business park in Perth, the acquisition of an A-grade office building in Melbourne and a fully underwritten institu... |
FNArena | MVF | 3 years ago |
|
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont... |
Stockhead | MVF | 3 years ago |